Evaluating the Difficulty involved in Designing Small Molecule Drugs to Inhibit Protein-Protein Interactions
Trends in Peptide and Protein Sciences,
Vol. 1 No. 4 (2017),
3 September 2017
,
Page 153-166
https://doi.org/10.22037/tpps.v1i4.18019
Abstract
The targeting of drugs to block protein-protein interactions (PPIs) has attracted great interest over recent years. Such targets, however, have been held to be difficult to inhibit using low molecular weight compounds, and as a consequence they are often branded as “undruggable”. This is partly because the interfaces involved are seen to be large, and the fact that they are generally regarded as being too smooth and too flat. In the work reported here, a series of quantitative systematic studies have been performed to determine the molecular area, roughness, curvature, and amino acid composition of the interfacial surfaces of PPIs, to determine the feasibility of designing small molecule drugs to inhibit these interactions. The X-ray crystal structures are analysed for a set of 48 PPIs involving G-protein, membrane receptor extracellular domain, and enzyme-inhibitor complexes. The protein partners involved in these PPIs are shown to have much larger interfacial areas than those for protein-small molecule complexes (≥ 900 Å2 vs ~250 Å2, respectively), and they have interfaces that are fairly smooth (with fractal dimensions close to 2) and quite flat (with mean surface curvatures in the order of ± 0.1 Å-1). The mean interfacial surface curvatures of the PPI protein partners, however, are seen to change upon complexation, some very significantly so. Despite the fact that the amino acid compositions of the PPI interface surfaces are found to be significantly different from that of the average protein surface (with variations according to the type of PPI), it is concluded that the prospects for designing low molecular weight PPI inhibitors that act in an orthosteric manner remain rather limited.
HIGHLIGHTS
•Mean interfacial surface curvatures have been determined for protein-protein interaction (PPI) partners in their complexed and uncomplexed states.
•Mean interfacial surface roughnesses have been determined for protein-protein interaction (PPI) partners in their complexed and uncomplexed states.
•Amino acid compositions have been determined for PPI interface surfaces and these compared with that for the average protein surface.
•Quantification of the PPI interfacial surface properties is used to assess the druggability of these targets.
- Drug Design
- Druggability
- Molecular Modelling
- Protein-protein interactions
How to Cite
References
Arkin, M. and J. Wells, (2004). "Small-molecule inhibitors of protein–protein interactions: progressing towards the dream." Nature Reviews Drug Discovery, 3(4): 301-317.
Bogan, A. and K. Thorn, (1998). "Anatomy of hot spots in protein interfaces." Journal of Molecular Biology, 280(1): 1-9.
Chothia, C. (1976). "The nature of the accessible and buried surfaces in proteins." Journal of Molecular Biology, 105(1): 1-12.
Conte, L., Chothia, C. and J. Janin, (1999). "The atomic structure of protein-protein recognition sites." Journal of Molecular Biology, 285(5): 2177-2198.
Corbi-Verge, C. and P. Kim, (2016). “Motif mediated protein-protein interactions as drug targets.” Cell Communication and Signaling, 14(1).
Gutmanas, A., Alhroub, Y., Battle, G. M., Berrisford, J. M., Bochet, E., Conroy, M. J., Dana, J. M., Fernandez Montecelo, M. A., van Ginkel, G., Gore, S. P. and P. Haslam, (2013). “PDBe: Protein Data Bank in Europe.” Nucleic Acids Research. 42(1): 285-291.
Hussain, A., Shanthi, V., Sheik, S., Jeyakanthan, J., Selvarani, P. and K. Sekar, (2002). "PDB Goodies – a web-based GUI to manipulate the Protein Data Bank file." Acta Crystallographica Section D Biological Crystallography, 58(8): 1385-1386.
Jones, S., and J. M. Thornton, (1996). “Principles of protein-protein interactions.” Proceedings of the National Academy of Sciences of the United States of America, 93(1): 13–20.
Kastritis, P., Moal, I., Hwang, H., Weng, Z., Bates, P., Bonvin, A. and J. Janin, (2011). “A structure-based benchmark for protein-protein binding affinity.” Protein Science, 20(3): 482-491.
Krissinel, E. and K. Henrick, (2007). "Inference of Macromolecular Assemblies from Crystalline State." Journal of Molecular Biology, 372(3): 774-797.
Laraia, L., McKenzie, G., Spring, D., Venkitaraman, A. and D. Huggins, (2015). "Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions." Chemistry & Biology, 22(6): 689-703.
Lipinski, C., Lombardo, F., Dominy, B. and P. Feeney, (2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings." Advanced Drug Delivery Reviews, 46(1-3): 3-26.
Lewis, M. and D. Rees, (1985). “Fractal surfaces of proteins.” Science, 230: 1163 1165.
Miller, S., Janin, J., Lesk, A. and C. Chothia, (1987). “Interior and surface of monomeric proteins” Journal of Molecular Biology, 196: 641 656.
Nero, T., Morton, C., Holien, J., Wielens, J. and M. Parker, (2014). "Oncogenic protein interfaces: small molecules, big challenges." Nature Reviews Cancer, 14(4): 248-262.
Raj, M., Bullock, B. and P. Arora, (2013). “Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions.” Bioorganic & Medicinal Chemistry, 21(14): 4051-4057.
Thangudu, R., Bryant, S., Panchenko, A. and T. Madej, (2012). "Modulating Protein–Protein Interactions with Small Molecules: The Importance of Binding Hotspots." Journal of Molecular Biology, 415(2): 443-453.
Toogood, P. (2002). "Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress†." Journal of Medicinal Chemistry, 45(8): 1543-1558.
Tsodikov, O., Record, M. and Y. Sergeev, (2002). "Novel computer program for fast exact calculation of accessible and molecular surface areas and average surface curvature." Journal of Computational Chemistry, 23(6): 600-609.
Vassilev, L. (2004). "In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2." Science, 303(5659): 844-848.
Wells, J., and C. McClendon, (2007). “Reaching for high-hanging fruit in drug discovery at protein–protein interfaces.” Nature, 450(7172): 1001-1009.
White, A., Westwell, A. and G. Brahemi, (2008). "Protein–protein interactions as targets for small-molecule therapeutics in cancer." Expert Reviews in Molecular Medicine, 10: e8. DOI: 10.1017/S1462399408000641.
- Abstract Viewed: 901 times
- PDF Downloaded: 338 times